//--> //--> //-->
Toggle navigation
Logout
Change account settings
EN
DE
ES
FR
A-Z
Beta
About EconBiz
News
Thesaurus (STW)
Research Skills
Help
EN
DE
ES
FR
My account
Logout
Change account settings
Login
Publications
Events
Your search terms
Search
Search options
All Fields
Title
Exact title
Subject
Author
Institution
ISBN/ISSN
Published in...
Publisher
Open Access only
Advanced
Search history
My EconBiz
Favorites
Loans
Reservations
Fines
You are here:
Home
Search: subject:"Chronic-myeloid-leukaemia"
Narrow search
Narrow search
Year of publication
From:
To:
Subject
All
Chronic-myeloid-leukaemia
4
Imatinib
3
Cost-effectiveness
2
Cost-utility
2
Interferon-alpha
2
Antineoplastics
1
Cost-analysis
1
Cytarabine
1
Decision-making
1
Fabry's-disease
1
Formularies
1
Hereditary-angioedema
1
Hydroxycarbamide
1
Orphan-drugs
1
Patient-compliance
1
Pricing
1
Pulmonary-hypertension
1
Regulatory-process
1
Reimbursement
1
Resource-use
1
treatment
1
more ...
less ...
Online availability
All
Undetermined
4
Type of publication
All
Article
4
Language
All
Undetermined
4
Author
All
Anstrom, Kevin J.
1
Baladi, Jean-Francois
1
Blankart, Carl Rudolf.
1
Cortes, Jorge
1
Dalziel, Kim
1
Darkow, Theodore
1
Feng, Weiwei
1
Garside, Ruth
1
Goldberg, George A.
1
Hatfield, Alan
1
Henk, Henry J.
1
Li, Yanhong
1
Reed, Shelby D.
1
Round, Ali
1
Schreyogg, Jonas Schreygg
1
Schulman, Kevin A.
1
Stargardt, Tom
1
Stein, Ken
1
Thomas, Simu K.
1
more ...
less ...
Published in...
All
PharmacoEconomics
4
Source
All
RePEc
4
Showing
1
-
4
of
4
Sort
relevance
articles prioritized
date (newest first)
date (oldest first)
1
Availability of and Access to Orphan Drugs: An International Comparison of Pharmaceutical Treatments for Pulmonary Arterial Hypertension, Fabry Disease, Hereditary Angioedema and
C...
Blankart, Carl Rudolf.
;
Stargardt, Tom
;
Schreyogg, …
- In:
PharmacoEconomics
29
(
2011
)
1
,
pp. 63-82
angioedema (HAE) and
chronic
myeloid
leukaemia
(CML). Indicators for availability were defined as (i) the indications for which …
Persistent link: https://www.econbiz.de/10010614375
Saved in:
2
Updated Estimates of Survival and Cost Effectiveness for Imatinib versus Interferon-alpha Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase
Chronic
Myeloid
Leukaemia
Reed, Shelby D.
;
Anstrom, Kevin J.
;
Li, Yanhong
; …
- In:
PharmacoEconomics
26
(
2008
)
5
,
pp. 435-446
)-alpha plus low-dose cytarabine in patients with chronic-phase
chronic
myeloid
leukaemia
. For patients treated with imatinib, we …
Persistent link: https://www.econbiz.de/10005449140
Saved in:
3
Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs: A Retrospective Analysis among Managed Care Patients with Chronic Myelogenous Leukaemia
Darkow, Theodore
;
Henk, Henry J.
;
Thomas, Simu K.
; …
- In:
PharmacoEconomics
25
(
2007
)
6
,
pp. 481-496
non-adherence with imatinib and healthcare costs for US managed care patients with
chronic
myeloid
leukaemia
(CML …
Persistent link: https://www.econbiz.de/10005404881
Saved in:
4
Cost Effectiveness of Imatinib Compared with Interferon-alpha or Hydroxycarbamide for First-Line Treatment of
Chronic
Myeloid
Leukaemia
Dalziel, Kim
;
Round, Ali
;
Garside, Ruth
;
Stein, Ken
- In:
PharmacoEconomics
23
(
2005
)
5
,
pp. 515-526
(hydroxyurea) for first-line treatment of
chronic
myeloid
leukaemia
. Design and Setting: A cost-utility (Markov) model within the …
Persistent link: https://www.econbiz.de/10005590496
Saved in:
Results per page
10
25
50
100
250
A service of the
zbw
×
Loading...
//-->